Verastem Oncology (VSTM)
5.89
0.00 (0.00%)
Upcoming Events
Latest Headlines
Verastem doses first patient in lung cancer trial for VS-7375
July 22, 2026 4:01 PM - StreetInsider
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
July 22, 2026 4:01 PM - BizWire
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Polar Capital Holdings Plc
July 8, 2026 9:49 AM - SEC Filing
Verastem (VSTM) PT Lowered to $14 at RBC Capital
July 7, 2026 8:00 AM - StreetInsider
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026 4:30 PM - BizWire
Form 144 Verastem, Inc. Filed by: Gagnon Robert E.
June 25, 2026 4:02 PM - SEC Filing
Form 4 Verastem, Inc. For: Jun 22 Filed by: Paterson Dan
June 24, 2026 4:45 PM - SEC Filing
Form 4 Verastem, Inc. For: Jun 22 Filed by: Calkins Daniel
June 24, 2026 4:45 PM - SEC Filing
RBC Capital on Verastem (VSTM): 'We think shares are undervalued'
June 24, 2026 9:37 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
June 24, 2026 6:45 AM - StreetInsider
BTIG Reiterates Buy Rating on Verastem (VSTM)
June 24, 2026 3:18 AM - StreetInsider
Form 8-K Verastem, Inc. For: Jun 23
June 23, 2026 4:03 PM - SEC Filing
Verastem reports early trial data for KRAS G12D cancer drug VS-7375
June 23, 2026 4:01 PM - StreetInsider
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
June 23, 2026 4:01 PM - BizWire
Form 144 Verastem, Inc. Filed by: Paterson Dan
June 22, 2026 7:51 PM - SEC Filing
Mizuho Reiterates Outperform Rating on Verastem (VSTM), maintain "June top pick"
June 18, 2026 6:36 AM - StreetInsider
Form 8-K Verastem, Inc. For: Jun 16
June 17, 2026 8:52 AM - SEC Filing
Verastem reports 86% six-month survival rate in pancreatic cancer trial
June 17, 2026 7:31 AM - StreetInsider
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
June 17, 2026 7:30 AM - BizWire
VERASTEM doses first patient in Phase 2 pancreatic cancer trial
June 16, 2026 4:01 PM - StreetInsider
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
June 16, 2026 4:01 PM - BizWire
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
June 15, 2026 4:01 PM - BizWire
Buy this biotech stock now, Mizuho urges
June 9, 2026 2:00 PM - StreetInsider
FDA grants fast track status to Verastem's lung cancer drug VS-7375
June 3, 2026 4:01 PM - StreetInsider
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally
June 3, 2026 4:01 PM - BizWire
Form S-8 Verastem, Inc.
May 29, 2026 4:41 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: BAILEY MICHAEL P
May 27, 2026 5:46 PM - SEC Filing
Form 3 Verastem, Inc. For: May 21 Filed by: BAILEY MICHAEL P
May 27, 2026 5:44 PM - SEC Filing
Form 144 Verastem, Inc. Filed by: Gagnon Robert E.
May 27, 2026 4:48 PM - SEC Filing
Verastem Oncology to Present at Jefferies Healthcare Conference
May 27, 2026 7:30 AM - BizWire
Form 4 Verastem, Inc. For: May 21 Filed by: Tollefson Karin Anna
May 26, 2026 6:24 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Stuglik Brian M
May 26, 2026 6:22 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Rowinsky Eric K
May 26, 2026 6:21 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: ROBERTSON MICHELLE
May 26, 2026 6:20 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Kapur Anil
May 26, 2026 6:18 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: Bunn Paul A.
May 26, 2026 6:13 PM - SEC Filing
Form 4 Verastem, Inc. For: May 21 Filed by: JOHNSON JOHN
May 26, 2026 6:12 PM - SEC Filing
Form 8-K Verastem, Inc. For: May 21
May 26, 2026 8:15 AM - SEC Filing
Verastem Oncology appoints Michael Bailey to board of directors
May 26, 2026 7:30 AM - StreetInsider
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
May 26, 2026 7:30 AM - BizWire
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Foresite Capital Fund VI LP
May 15, 2026 4:30 PM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:08 AM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: RTW INVESTMENTS, LP
May 15, 2026 8:43 AM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
May 15, 2026 6:36 AM - SEC Filing
Verastem (VSTM) PT Lowered to $14 at Mizuho
May 14, 2026 6:38 AM - StreetInsider
Verastem Oncology to Present at Upcoming Investor Conferences
May 12, 2026 7:30 AM - BizWire
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
May 8, 2026 7:30 AM - BizWire
Verastem (VSTM) PT Lowered to $18 at BTIG
May 8, 2026 6:56 AM - StreetInsider
Verastem Oncology (VSTM) Misses Q1 EPS by 43c
May 7, 2026 4:24 PM - StreetInsider
Form 8-K Verastem, Inc. For: May 07
May 7, 2026 4:14 PM - SEC Filing
Form 10-Q Verastem, Inc. For: Mar 31
May 7, 2026 4:09 PM - SEC Filing
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 7, 2026 4:01 PM - BizWire
Form 4 Verastem, Inc. For: May 04 Filed by: Paterson Dan
May 6, 2026 4:01 PM - SEC Filing
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
April 30, 2026 7:30 AM - BizWire
Full Article List
